Isofol Medical Expands Phase Ib/II Trial for Arfolitixorin in Colorectal Cancer Following German Regulatory Approval
Key Insights
German regulatory authority BfArM has approved an optimized design for Isofol Medical's ongoing phase Ib/II study of arfolitixorin, expanding inclusion criteria from 45% to 90% of colorectal cancer (search) patients.
The phase II portion will now include a control arm for direct comparison with leucovorin, the current leading folate-based medicine, strengthening the trial's robustness.
Study expansion includes additional chemotherapy regimens and will increase from one to 10-15 study centers across multiple European countries to accelerate patient recruitment.
Isofol Medical AB has received regulatory approval from the German authority BfArM to optimize the design of its ongoing phase Ib/II clinical study evaluating arfolitixorin, a next-generation folate treatment for colorectal cancer (search). The approval significantly broadens the trial's scope and introduces a direct comparison with the current standard of care.
Expanded Patient Population and Study Design
The protocol amendment expands the potential patient population from approximately 45% to 90% of those affected by metastatic colorectal cancer (search). The phase II study will no longer exclusively include patients with RAS (search)-mutated metastatic colorectal cancer, but will also encompass patients with RAS-wild-type tumors.
The phase II portion will now include a control arm enabling direct comparison of arfolitixorin with leucovorin, the current leading folate-based medicine. This addition strengthens the study's design and provides crucial comparative data for regulatory discussions and potential business partnerships.
Broadened Treatment Regimens
The amendment allows concomitant treatment with additional types of chemotherapy regimens, further expanding the eligible patient population. While the study currently recruits only patients treated with the standard FOLFOX regimen (5-FU, oxaliplatin and folate) in combination with bevacizumab, it will now also include patients treated with FOLFIRI (5-FU, irinotecan and folate) in combination with anti-EGFR (search) treatment.
Multi-Center European Expansion
To accelerate patient recruitment, the study will expand from its current single center at Charité – Universitätsmedizin Berlin to 10-15 study centers across multiple European countries. BfArM has already approved the addition of one more German university hospital for the phase Ib portion of the trial, with patient enrollment expected to begin shortly.
"It is very encouraging that the German regulatory authority has approved the protocol amendment," said Petter Segelman Lindqvist, CEO of Isofol. "With these adjustments, the study becomes even more robust, and we also gain the opportunity to conduct comparisons between arfolitixorin and leucovorin already in phase II, which will further enhance our discussions with potential business partners."
Clinical Context and Unmet Need
Colorectal cancer (search) represents the third most common form of cancer (search) globally and the second most common cause of cancer-related death, according to the World Health Organization. The significant disease burden underscores the high need for new treatments in this therapeutic area.
Arfolitixorin is designed to enhance the efficacy of established standard treatments for several types of solid tumors. The drug candidate is patent-protected and based on extensive clinical research, with an optimized dosing regimen currently under evaluation in the phase Ib/II study.
The expanded inclusion criteria move Isofol closer to covering the entire patient population intended as the initial label for arfolitixorin following potential marketing authorization, positioning the company for broader clinical impact in colorectal cancer (search) treatment.